Want to see TLPH full AI Analyst Report?
TLPH Stock Chart & Stats
$1.35
-$0.02(-1.46%)
At close: 4:00 PM EDT
$1.35
-$0.02(-1.46%)
Day’s Range― - ―
52-Week Range$0.39 - $1.57
Previous CloseN/A
Volume89.66K
Average Volume (3M)2.97M
Market Cap
$66.43M
Enterprise Value$37.54
Total Cash (Recent Filing)$21.11M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.88
Next Earnings
Aug 19, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding51,899,647
10 Day Avg. Volume675,544
30 Day Avg. Volume2,969,035
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)2.84
Price to Sales (P/S)1726.72
P/FCF Ratio-4.25
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue0.04
Enterprise Value/Gross Profit0.04
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.17Price Target Upside134.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.24
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Clean Balance SheetZero reported debt and positive equity provide durable financial flexibility for a clinical-stage company. A clean balance sheet lowers refinancing pressure, supports negotiating leverage or partnerships, and reduces the probability that near-term development delays immediately force distressed financing choices.
Fast, Low-complexity Clinical ReadoutsShort primary/secondary endpoints materially shorten time-to-data versus typical trials, compressing the development timeline and lowering cumulative burn per trial. Faster readouts enable quicker regulatory decisions, clearer partner/financing discussions, and reduce prolonged execution exposure for the program.
Strong Site And KOL EngagementHigh investigator engagement and KOL endorsement improve trial reliability, enrollment efficiency and regulatory credibility. Deep site alignment reduces variability and supports consistent operational execution, increasing the chance of interpretable data and smoother regulatory interactions long-term.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flows create a structural funding requirement for continued development. Without durable revenue, the company must repeatedly access capital, which can be dilutive or costly, and raises the risk that clinical or timing hiccups force suboptimal financing choices.
No Meaningful Revenue / Deep LossesAn absence of recurring revenue and very negative margins mean the business model is not yet self-sustaining. Profitability depends entirely on successful clinical outcomes or external funding, leaving long-term viability contingent on binary development and regulatory events rather than operating cash-generation.
Reliance On Conditional Financing TranchesMaterial near-term funding is contingent on milestone achievement and timing, which concentrates execution risk. If enrollment or data timing slips, these tranches may be delayed or not close, forcing dilutive or expensive alternatives and potentially interrupting the path to regulatory submission and commercialization.
Talphera News
TLPH FAQ
What was Talphera’s price range in the past 12 months?
Talphera lowest stock price was $0.39 and its highest was $1.57 in the past 12 months.
What is Talphera’s market cap?
Talphera’s market cap is $66.43M.
When is Talphera’s upcoming earnings report date?
Talphera’s upcoming earnings report date is Aug 19, 2026 which is in 16 days.
How were Talphera’s earnings last quarter?
Talphera released its earnings results on May 13, 2026. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.067 by $0.027.
Is Talphera overvalued?
According to Wall Street analysts Talphera’s price is currently Undervalued.
Does Talphera pay dividends?
Talphera does not currently pay dividends.
What is Talphera’s EPS estimate?
Talphera’s EPS estimate is -0.06.
How many shares outstanding does Talphera have?
Talphera has 51,899,647 shares outstanding.
What happened to Talphera’s price movement after its last earnings report?
Talphera reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.067. Following the earnings report the stock price went down -0.444%.
Which hedge fund is a major shareholder of Talphera?
Currently, no hedge funds are holding shares in TLPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Talphera Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.17 (134.57% Upside)
$3.17 (134.57% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.2%
Last 30 Days ▲ 3.3%
Last 30 Days ▲ 3.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-7.75%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
101.10%
Trailing 12-Months
Company Description
Talphera
Talphera, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapeutic products intended for use in carefully monitored medical environments. Their lead experimental candidate is Niyad, a lyophilized (freeze-dried) formulation of nafamostat. This anticoagulant is currently being assessed under an investigational device exemption for its application in extracorporeal circuits. The company's development pipeline also features LTX-608, a potential anti-inflammatory and antiviral agent being explored for the treatment of numerous conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis. Furthermore, Talphera is advancing Fedsyra, a pre-filled syringe containing ephedrine, and PFS-02, a pre-filled syringe containing phenylephrine. Established in 2005, the company was previously known as AcelRx Pharmaceuticals, Inc. It adopted the name Talphera, Inc. in January 2024 and maintains its corporate headquarters in San Mateo, California.
TLPH Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong clinical and operational momentum: enrollment has surpassed the 50% milestone, sites and KOLs reported favorable feedback on dosing simplicity and stability, and management expects a rapid top-line read in H2 2026 with a PMA plan for 2027. However, the company faces higher operating expenses and depends on two conditional financing tranches (~$16M) to fund the path to potential approval, with enrollment variability and financing contingency as primary risks. Overall, positive progress is balanced against execution and financing risk, but the highlights outweigh the lowlights.View all TLPH earnings summariesTLPH Stock 12 Month Forecast
Average Price Target
$3.17
▲(134.57% Upside)
Technical Analysis
Ownership Overview
6.01% Insiders
1.48% Mutual Funds
0.60% Other Institutional Investors
90.56% Public Companies and
Individual Investors